Identification Insertion/Deletion 6bp of 3’-Untranslated Region Thymidylate Synthase Gene in Orbital Region Basal Cell Carcinoma
Article Sidebar
Abstract
Background: Basal cell carcinoma (BCC) is the most common eyelid malignancy tumor. The risk factor for development of BCC related to environtmental factor especially prolonged sun exposure and individual factor. One of the internal risk factor contributes to BCC development is genetic instability including defects in folic acid synthesis or DNA synthesis. Enzyme participates in this process is 3’-untranslated region Thymidylate synthase gene (UTR TS). This study is to identify the insertion or deletion of 6bp of 3’-UTR TS gene in orbital region BCC.
Methods: This study was a descriptive explorative study with case series which involved 13 orbital region basal cell carcinoma (BCC). The diagnosis was based on histological examination of the tumor. The frequencies of insertion/deletion 6bp of 3’-UTR TS gene were assessed by Polymerase Chain Reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses using Dra I as restriction enzyme.
Results: Thirteen patients consist of 9 males (69%) and 4 females (31%). Majority of subjects have history of sun exposure. The most common type of BCC is nodular type (80%). There was two subject with recurrent case. Identification result of insertion/deletion 6bp 3’-UTR TS gene found heterozigot mutant -6bp/+6bp in 7 samples (54%) at 152bp band and 158 bp band, homozigot mutant -6bp/-6bp in 6 samples (46%) at 152bp band.
Conclusion: The results of this study were 7 samples (54%) are heterozigot mutant -6bp/+6bp and 6 sample (46%) are homozigot mutant -6bp/-6bp.
Full text article
References
2. Lear W, Dahlke E, Murray CA.Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 11(1):19-30, 2007.
3. Yahya YF dkk, Profil Karsinoma Sel Basal Primer di RSUP M. Hoesin Palembang, (MDVI 2011; 38/2:78-83).
4. Kim GK, Rossa JQ, Bellew S, Skin Cancer in Asia, Clinical aesthetic dermatology, 2009, 2, 39-42.
5. Suriadiredja AS, Editorial Epidemiologi Kanker Kulit, Departemen IK Kulit dan Kelamin FKUI/RSUPN dr.Cipto Mangunkusumo.
6. Claudia Mateoui, Claudia-Valentina Georgescu. Cristina Simionescu. Histopathological study of Basal Cell Carcinoma. Current Health Science Journal. 2009. Vol.35, No.2.
7. Cheng-Hsien Chang, Sheng-Ming Chang, Yu-Hung Lai, Jason Huang. Eyelid Tumors in Southern Taiwan: A 5-year Survey from a Medical University. Kaohsiung J Med Sci 2003;19:549–54
8. N.R.Telfer, G.B.Colver andP.W.Bowers. Guidelines for the management of basal cell carcinoma. British Journal of Dermatology 1999; 141: 415-423.
9. Lacour JP. Carcinogenesis of basal cell carcinomas:genetics and molecular mechansisms. Br J Dermatol 2002;146(Suppl 61):17–19.
10. Vantuchoya Y, Curik R, histological types of basal cell carcinoma, Scripta Medica, 79 (5-6), 261-270, 2006.
11. Leffel DJ, Headington JT, Wong DS et al. Aggressive growth basal cell carcinoma in young adult. Arch Drmatol 1991, 127: 1663-1667.
12. Joshua M. Berlin, MD, Michael R. Warner, MD, and Philip L. Bailin, MD. Metastatic Basal Cell Carcinoma Presenting as Unilateral Axillary Lymphadenopathy: Report of a Case and Review of the Literature. Dermatol Surg 2002;28:1082–1084.
13. Recep Bedir, Rustu Kose, Hasan gucer, Nursel dilek. Nodular Basal Cell Carcinoma in non exposed skin: a case report. Egyptian Dermatology online journal. Vol.7 No. 2:9, Desember 2011
14. Tilli CML, Steensel MAM, et al in Molecular aetiology and pathogenesis of basal cell carcinoma British Journal of dermatology, 152, 1108 – 1124,2005
15. Kim Y I. cancer Epidemiology Biomarker. Prev. 2004, 13,511-519
16. Sang Yoon Kang, sung Jun Lee, Seung Ho Hong et al. Polymorphisms of 5,10-methylenetetrahydrofolatereductase and thymydilate synthase in squamous Cell Carcinoma and Basal Cell Carcinoma of the skin.Molecular Medicine Reports,2010. Vol 3:741-747
17. Sanjay Agarwalla, Sherry LaPorte, Lu Liu, Janet Finer- Moore, Robert M. Stroud, and Daniel V. Santi. A Novel dCMP Methylase by Engineering Thymidylate Synthase. Biochemistry 1997, 36, 15909-15917
18. Goto Y, Yue L, Yokoi A, Nishimura R, Uehara T, Koizumi S and Saikawa Y: A novel single-nucleotide polymorphism in 3’-Untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 7:1952-1956, 2001
19. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Ibal S, Lens HJ and Ladner RD: A6 bp polymorphism in the tymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319-327, 2004
20. Festa F, Kumar R, Sanyal S, Unden B, Nordfors L, Lindholm B, Snellman E, Schalling M, Forsti A and Hemminki K : Basal cell carcinoma and variants in gene coding for immune response, DNA repair, folate, and iron metabolism. Mutat Res 574:105-111, 2005
21. Kastan MB, onkyekwere O, Sidransky D et al.participant of p53 protein in the cellular response to DNA damage. Cancer res 1991; 51; 6304-11
22. Mannor GE, Chern PL, Barnette D. Eyelid and Periorbital Skin Basal Cell carcinoma, oculoplastic Management and Surgery, International Ophthalmology Clinics, 49, 1-16, 2009.
23. Nemet AY et al, Management of Periocular Basal and Squamous Cell carcinoma: a series of 485 cases. American Journal of Ophthalmology, 2006, 142: 293-297
24. Ibrar Hussain, Mahmooda Soni, Bakht Samar Khan, Mohammad Daud Khan.
25. Basal Cell Carcinoma Presentation,Histopathological Features and Correlation with Clinical Behaviour. Pak J Ophthalmol 2011, Vol. 27 No. 1
26. Homo sapiens thymidylate synthase gene, partial cds; and upstream region. Availabale at http://www.metalife.com/ Genbank/5478495